Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:CTST NASDAQ:EPIX NASDAQ:ETON NASDAQ:SVRA NASDAQ:ZYNE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCTSTCannTrustC$0.64C$0.64C$0.38▼C$8.17C$90.27MN/AN/AN/AEPIXESSA Pharma$0.20$0.39$0.18▼$6.45$9.52M1.572.99 million shsN/AETONEton Pharmaceuticals$18.46-0.4%$18.54$7.58▼$23.00$495.06M1.16330,087 shs145,407 shsSVRASavara$4.36+5.8%$3.53$1.89▼$4.42$753.57M0.461.32 million shs1.65 million shsZYNEZynerba Pharmaceuticals$1.30$1.30$0.25▼$1.40$70.12M1.32515,333 shsN/AAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCTSTCannTrust0.00%0.00%0.00%0.00%0.00%EPIXESSA Pharma0.00%0.00%+0.50%-89.30%-96.25%ETONEton Pharmaceuticals0.00%+1.54%-8.34%+19.87%+127.06%SVRASavara0.00%+20.78%+25.65%+68.99%+27.86%ZYNEZynerba Pharmaceuticals0.00%0.00%0.00%0.00%0.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCTSTCannTrustC$0.64C$0.64C$0.38▼C$8.17C$90.27MN/AN/AN/AEPIXESSA Pharma$0.20$0.39$0.18▼$6.45$9.52M1.572.99 million shsN/AETONEton Pharmaceuticals$18.46-0.4%$18.54$7.58▼$23.00$495.06M1.16330,087 shs145,407 shsSVRASavara$4.36+5.8%$3.53$1.89▼$4.42$753.57M0.461.32 million shs1.65 million shsZYNEZynerba Pharmaceuticals$1.30$1.30$0.25▼$1.40$70.12M1.32515,333 shsN/AAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCTSTCannTrust0.00%0.00%0.00%0.00%0.00%EPIXESSA Pharma0.00%0.00%+0.50%-89.30%-96.25%ETONEton Pharmaceuticals0.00%+1.54%-8.34%+19.87%+127.06%SVRASavara0.00%+20.78%+25.65%+68.99%+27.86%ZYNEZynerba Pharmaceuticals0.00%0.00%0.00%0.00%0.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCTSTCannTrust 0.00N/AN/AN/AEPIXESSA Pharma 1.75Reduce$2.00894.04% UpsideETONEton Pharmaceuticals 2.40Hold$29.6760.71% UpsideSVRASavara 2.78Moderate Buy$7.8379.66% UpsideZYNEZynerba Pharmaceuticals 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest EPIX, ETON, CTST, ZYNE, and SVRA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/25/2025ETONEton PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/25/2025SVRASavaraWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/23/2025SVRASavaraCitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform10/23/2025SVRASavaraJMP SecuritiesSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetMarket Outperform$8.00 ➝ $11.0010/20/2025SVRASavaraWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$7.0010/14/2025SVRASavaraLifesci CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy10/8/2025EPIXESSA PharmaWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/8/2025ETONEton PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025SVRASavaraWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/7/2025ETONEton PharmaceuticalsZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold9/27/2025EPIXESSA PharmaWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)(Data available from 10/26/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCTSTCannTrustC$35.22M2.56N/AN/AN/A∞EPIXESSA PharmaN/AN/AN/AN/A$2.81 per shareN/AETONEton Pharmaceuticals$39.01M12.69N/AN/A$0.94 per share19.64SVRASavaraN/AN/AN/AN/A$1.00 per shareN/AZYNEZynerba PharmaceuticalsN/AN/AN/AN/A$1.01 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCTSTCannTrust-C$10.46MN/A0.00∞N/AN/AN/AN/AN/AEPIXESSA Pharma-$28.54M-$0.56N/AN/AN/AN/A-21.71%-21.22%12/16/2025 (Estimated)ETONEton Pharmaceuticals-$3.82M-$0.16N/A36.92N/A-7.10%-0.73%-0.22%11/6/2025 (Estimated)SVRASavara-$95.88M-$0.50N/AN/AN/AN/A-69.05%-54.84%11/11/2025 (Estimated)ZYNEZynerba Pharmaceuticals-$35.04M-$0.80N/AN/AN/AN/A-90.03%-72.62%N/ALatest EPIX, ETON, CTST, ZYNE, and SVRA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/11/2025Q3 2025SVRASavara-$0.13N/AN/AN/AN/AN/A11/6/2025Q3 2025ETONEton Pharmaceuticals$0.13N/AN/AN/A$20.47 millionN/A8/13/2025Q3 2025EPIXESSA Pharma-$0.17-$0.09+$0.08-$0.09N/AN/A8/13/2025Q1 2025SVRASavara-$0.12-$0.14-$0.02-$0.14N/AN/A8/7/2025Q2 2025ETONEton Pharmaceuticals-$0.01-$0.10-$0.09-$0.10$16.71 million$18.93 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCTSTCannTrustN/AN/AN/AN/AN/AEPIXESSA Pharma$1.69839.96%N/AN/A N/AETONEton PharmaceuticalsN/AN/AN/AN/AN/ASVRASavaraN/AN/AN/AN/AN/AZYNEZynerba PharmaceuticalsN/AN/AN/AN/AN/ALatest EPIX, ETON, CTST, ZYNE, and SVRA DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date1/1/2100EPIXESSA Pharma--$1.698/25/20258/19/20258/22/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCTSTCannTrustN/AN/AN/AEPIXESSA PharmaN/A69.0669.06ETONEton Pharmaceuticals1.141.771.16SVRASavara0.2511.0811.08ZYNEZynerba PharmaceuticalsN/A3.433.43Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCTSTCannTrust0.03%EPIXESSA Pharma75.12%ETONEton Pharmaceuticals27.86%SVRASavara87.93%ZYNEZynerba Pharmaceuticals11.23%Insider OwnershipCompanyInsider OwnershipCTSTCannTrustN/AEPIXESSA Pharma15.50%ETONEton Pharmaceuticals16.03%SVRASavara5.33%ZYNEZynerba Pharmaceuticals13.04%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCTSTCannTrust576141.49 millionN/AOptionableEPIXESSA Pharma5047.31 million39.98 millionOptionableETONEton Pharmaceuticals2026.82 million22.52 millionOptionableSVRASavara20172.84 million163.63 millionOptionableZYNEZynerba Pharmaceuticals2553.94 million46.91 millionOptionableEPIX, ETON, CTST, ZYNE, and SVRA HeadlinesRecent News About These CompaniesHarmony Fails Pivotal Fragile X Syndrome Trial, Blames High Placebo ResponseSeptember 25, 2025 | biospace.comBHarmony's pivotal Fragile X trial flops as high placebo response creates discordSeptember 25, 2025 | fiercebiotech.comFFragile X Syndrome Market to Experience Notable Growth in Forecast Span by 2034, DelveInsight Predicts | Novartis, Neuren Pharma, Roche, Seaside Therapeutics, Inc., Marinus ...August 28, 2025 | theglobeandmail.comEurope’s cannabis pharmaceuticals market matures amid cautious investmentAugust 4, 2025 | finance.yahoo.com22q11.2 Deletion Syndrome Market Research Report 2025: Zynerba Pharmaceuticals is at the Forefront with Its Clinical-stage Therapy Zygel (ZYN002)June 25, 2025 | globenewswire.comHarmony Biosciences: If It Ain't BrokeJune 5, 2025 | seekingalpha.comUS Penny Stocks To Watch In October 2024October 28, 2024 | uk.finance.yahoo.comDiscover 3 US Penny Stocks With Market Caps Over $70MOctober 24, 2024 | uk.finance.yahoo.comAtea Pharmaceuticals Leads The Charge In US Penny Stocks SpotlightOctober 22, 2024 | uk.finance.yahoo.comGW Pharma's cannabis-derived epilepsy drug approved in EUOctober 7, 2024 | pharmaphorum.comPFragile X Syndrome Therapeutic Pipeline Research Report 2024 Featuring Zynerba, Tetra Discovery Partners, Nova Mentis, Neuren Pharmaceuticals, and Tetra Discovery PartnersJuly 31, 2024 | globenewswire.comHarmony Biosciences Reports Strong Third Quarter 2023 Financial ResultsOctober 31, 2023 | finance.yahoo.comWhy Shares of Harmony Bioscience Are Falling on FridayOctober 13, 2023 | fool.comNew Possibilities For Cannabinoid Treatments: Acquisition To Transform Neuropsychiatric Disorder TherapiesOctober 11, 2023 | markets.businessinsider.comHARMONY BIOSCIENCES COMPLETES ACQUISITION OF ZYNERBA PHARMACEUTICALS AND EXPANDS PIPELINEOctober 11, 2023 | finance.yahoo.comH.C. Wainwright analysts reiterates a Buy rating for Zynerba Pharmaceuticals Inc (ZYNE)October 10, 2023 | knoxdaily.comKAnalysts: ZYNE stock price target of $1.25 in 12 monthsOctober 5, 2023 | knoxdaily.comKImportant Information for Zynerba Pharmaceuticals Stockholders to Tender Shares for the Harmony Transaction: Process and InstructionsOctober 4, 2023 | finance.yahoo.comExamining the Potential Price Growth of Zynerba Pharmaceuticals Inc (ZYNE)October 2, 2023 | knoxdaily.comK20 Countries With Highest Rate of EpilepsySeptember 29, 2023 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeEPIX, ETON, CTST, ZYNE, and SVRA Company DescriptionsCannTrust NYSE:CTSTCannTrust Holdings Inc. produces and sells medical and recreational cannabis in Canada. It sells dried cannabis and cannabis extracts to the medical patients. CannTrust Holdings Inc. was incorporated in 2015 and is headquartered in Vaughan, Canada.ESSA Pharma NASDAQ:EPIX$0.20 0.00 (0.00%) As of 10/13/2025ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company's lead candidate EPI-7386, an androgen receptor based resistance mechanisms that develop in patients with castration-resistant prostate cancer and metastatic castration-resistant prostate cancer. It has collaboration agreements with Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.Eton Pharmaceuticals NASDAQ:ETON$18.46 -0.08 (-0.43%) Closing price 10/24/2025 04:00 PM EasternExtended Trading$18.46 0.00 (0.00%) As of 10/24/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1. It also provides Zeneo hydrocortisone autoinjector for the treatment of adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.Savara NASDAQ:SVRA$4.36 +0.24 (+5.83%) Closing price 10/24/2025 04:00 PM EasternExtended Trading$4.40 +0.04 (+0.94%) As of 10/24/2025 06:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Savara Inc., formerly Mast Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients. Molgradex is an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor. It is developing Molgradex for the treatment of autoimmune pulmonary alveolar proteinosis, a rare lung disease. AIR001 is a sodium nitrite solution for inhalation via nebulization. AIR001 is in Phase II clinical development for the treatment of heart failure with preserved ejection fraction, also known as diastolic heart failure or heart failure with preserved systolic function.Zynerba Pharmaceuticals NASDAQ:ZYNEZynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. The company focuses on developing pharmaceutically produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. It is developing Zygel, a pharmaceutically produced cannabidiol formulated as a permeation-enhanced gel for transdermal delivery. The company was formerly known as AllTranz, Inc. and changed its name to Zynerba Pharmaceuticals, Inc. in August 2014. Zynerba Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Devon, Pennsylvania. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 10/20 - 10/24 Freeport-McMoRan Posts Strong Earnings Despite Indonesia Shutdown Tractor Supply Stock Looks Like a Buy-and-Hold Winner Tesla’s Earnings Review: Does the Juice Justify the Squeeze? Warner Bros. Bidding War Potential: How High Could WBD Shares Go? Fal.Con Europe Could Be CrowdStrike’s Early Earnings Catalyst Logitech Eyes Breakout Before Earnings—Citigroup Sees 30% Upside Boeing Takes Off as FAA Greenlights 737 MAX Production Boost Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
